BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:TAK-360 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of TAK-360\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06952699-11361@assetmemo.bio
DTSTAMP:20261121T005613Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:TAK-360: Phase 2 readout est. (NCT06952699)
DESCRIPTION:TAK-360\, phase 2\, Narcolepsy.\nStudy: A Study of TAK-360 in A
 dults With Narcolepsy Without Cataplexy (NT2)\nEstimated primary completio
 n: 30 November 2026. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 tak-360#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06952699
URL:https://assetmemo.bio/drug/tak-360#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06812078-11361@assetmemo.bio
DTSTAMP:20261121T005613Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:TAK-360: Phase 2 readout est. (NCT06812078)
DESCRIPTION:TAK-360\, phase 2.\nStudy: A Study of TAK-360 in Adults With Id
 iopathic Hypersomnia\nEstimated primary completion: 30 November 2026. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/tak-360#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06812078
URL:https://assetmemo.bio/drug/tak-360#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07633301-11361@assetmemo.bio
DTSTAMP:20261121T005613Z
DTSTART;VALUE=DATE:20271128
DTEND;VALUE=DATE:20271129
SUMMARY:TAK-360: Phase 2 readout est. (NCT07633301)
DESCRIPTION:TAK-360\, phase 2\, Narcolepsy.\nStudy: A Study of TAK-360 in A
 dults With Narcolepsy Type 1 (Narcolepsy With Cataplexy)\nEstimated primar
 y completion: 28 November 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/tak-360#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT07633301
URL:https://assetmemo.bio/drug/tak-360#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07646678-11361@assetmemo.bio
DTSTAMP:20261121T005613Z
DTSTART;VALUE=DATE:20310615
DTEND;VALUE=DATE:20310616
SUMMARY:TAK-360: Phase 2/3 readout est. (NCT07646678)
DESCRIPTION:TAK-360\, phase 2/3\, Narcolepsy.\nStudy: A Study of TAK-360 in
  People With Narcolepsy or Idiopathic Hypersomnia\nEstimated primary compl
 etion: 15 June 2031. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 tak-360#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07646678
URL:https://assetmemo.bio/drug/tak-360#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
